AstraZeneca

Sino Biopharmaceutical announced plans to acquire LaNova Medicines for up to $951 million, with a net payment of approximately $500 million after accounting for cash holdings.

Ascentage Pharma completed a $192.3 million share placement that was oversubscribed by eight times, demonstrating strong investor confidence in the company's cancer-focused pipeline.

AstraZeneca is conducting an observational cohort study titled "Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation" to assess the safety and effectiveness of their anticoagulation reversal agent in real-world settings.

Eolas Therapeutics has secured full development rights to AZD4041 from AstraZeneca, a highly selective orexin-1 receptor antagonist targeting opioid use disorder and other substance use disorders.

JCR Pharmaceuticals has entered into a licensing agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsid technology to develop genomic medicines for rare diseases.

Flightpath Biosciences has licensed lolamicin, a novel antibiotic developed at the University of Illinois that targets gram-negative bacteria while preserving beneficial gut microbes.

Briquilimab demonstrated remarkable efficacy in chronic spontaneous urticaria (CSU) with 89% of patients achieving complete response by week 2 in valid cohorts of the BEACON Phase 1b/2a trial.

Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.

The Scottish Medicines Consortium has recommended Theramex's Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women at very high risk of fracture through NHS Scotland.

AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.